

# PHASE 3 TRIALS IN MULTIPLE SCLEROSIS

Updated August 2018. This list highlights notable Phase 3 trials but is not inclusive of all studies.

Phase 3 trials are conducted to definitively determine effectiveness and gain a better understanding of possible side effects.

## Abbreviations Key:

CIS – clinically isolated syndrome

COMP/ALT – interventions considered to be outside the realm of conventional medicine

MED – medical therapy, including medications and medical procedures

PP - primary progressive

REHAB – rehabilitation intervention

Relapsing - relapsing forms of MS include RR MS as well as progressive MS in those individuals who continue to experience relapses.

RIS - radiologically isolated syndrome (imaging findings without symptoms)

RR - relapsing-remitting

SP - secondary progressive

| Study title   | Recruitment status     | Type of Intervention | Sponsor/ Collaborators                   | Type of MS           | Number of participants | Link for more information   |
|---|------------------------|----------------------|--|----------------------|------------------------|---|
| <b>Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis</b>  | Active, not recruiting | MED                  | Actelion                                 | Relapsing            | 1100                   | <a href="https://ClinicalTrials.gov/show/NCT02425644">https://ClinicalTrials.gov/show/NCT02425644</a> |
| <b>A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period</b> | Active, not recruiting | MED                  | Centre Hospitalier Universitaire de Nice | CIS                  | 5                      | <a href="https://ClinicalTrials.gov/show/NCT02587195">https://ClinicalTrials.gov/show/NCT02587195</a> |
| <b>Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis</b>  | Active, not recruiting | MED                  | Novartis Pharma.                         | Relapsing, pediatric | 215                    | <a href="https://ClinicalTrials.gov/show/NCT01892722">https://ClinicalTrials.gov/show/NCT01892722</a> |

| <b>Study title</b>   | <b>Recruitment status</b> | <b>Type of Intervention</b> | <b>Sponsor/ Collaborators</b>                                   | <b>Type of MS</b>                   | <b>Number of participants</b> | <b>Link for more information</b>  |
|--|---------------------------|-----------------------------|---|-------------------------------------|-------------------------------|---|
| <b>Effect of MD1003 in Spinal Progressive Multiple Sclerosis</b>   | Active, not recruiting    | COMP/ALT                    | MedDay Pharma. SA   | SP, PP, with spasticity in the legs | 144                           | <a href="https://ClinicalTrials.gov/show/NCT02220933">https://ClinicalTrials.gov/show/NCT02220933</a> |
| <b>Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis</b> | Active, not recruiting    | MED                         | Novartis Pharma.   Novartis                                     | Relapsing                           | 928                           | <a href="https://ClinicalTrials.gov/show/NCT02792218">https://ClinicalTrials.gov/show/NCT02792218</a> |
| <b>Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)</b>   | Active, not recruiting    | COMP/ALT                    | MedDay Pharma. SA   | SP, PP                              | 600                           | <a href="https://ClinicalTrials.gov/show/NCT02936037">https://ClinicalTrials.gov/show/NCT02936037</a> |
| <b>A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis</b>                  | Enrolling by invitation   | MED                         | Celgene   | Relapsing                           | 2350                          | <a href="https://ClinicalTrials.gov/show/NCT02576717">https://ClinicalTrials.gov/show/NCT02576717</a> |
| <b>App Based Dexterity Training in Multiple Sclerosis</b>  | Recruiting                | REHAB                       | Luzerner Kantonsspital   University Hospital Inselspital, Berne | All types                           | 70                            | <a href="https://ClinicalTrials.gov/show/NCT03369470">https://ClinicalTrials.gov/show/NCT03369470</a> |
| <b>A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1</b>               | Enrolling by invitation   | MED                         | Alkermes, Inc.  | RR                                  | 935                           | <a href="https://ClinicalTrials.gov/show/NCT02634307">https://ClinicalTrials.gov/show/NCT02634307</a> |

| Study title  | Recruitment status      | Type of Intervention | Sponsor/ Collaborators         | Type of MS    | Number of participants | Link for more information   |
|--|-------------------------|----------------------|--------------------------------|---------------|------------------------|---|
| <b>This is an Extension Study of the Roche P-trial to Investigate Safety and Effectiveness of a Single Ocrelizumab Dose in Participants With Multiple Sclerosis (MS)</b> | Recruiting              | MED                  | Hoffmann-La Roche              | Relapsing, PP | 1500                   | <a href="https://ClinicalTrials.gov/show/NCT03599245">https://ClinicalTrials.gov/show/NCT03599245</a> |
| <b>Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis</b>  | Enrolling by invitation | MED                  | Actelion                       | Relapsing     | 800                    | <a href="https://ClinicalTrials.gov/show/NCT03232073">https://ClinicalTrials.gov/show/NCT03232073</a> |
| <b>Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis</b>   | Recruiting              | MED                  | University of Colorado, Denver | Relapsing     | 200                    | <a href="https://ClinicalTrials.gov/show/NCT02980042">https://ClinicalTrials.gov/show/NCT02980042</a> |

| Study title   | Recruitment status | Type of Intervention | Sponsor/ Collaborators | Type of MS    | Number of participants | Link for more information   |
|---|--------------------|----------------------|------------------------|---------------|------------------------|---|
| <b>A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS).</b> | Not yet recruiting | MED                  | Genentech, Inc.        | Relapsing, PP | 150                    | <a href="https://ClinicalTrials.gov/show/NCT03606460">https://ClinicalTrials.gov/show/NCT03606460</a> |
| <b>Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)</b>                     | Recruiting         | MED                  | Actelion               | Relapsing     | 600                    | <a href="https://ClinicalTrials.gov/show/NCT02907177">https://ClinicalTrials.gov/show/NCT02907177</a> |

| Study title   | Recruitment status     | Type of Intervention | Sponsor/ Collaborators             | Type of MS           | Number of participants | Link for more information   |
|---|------------------------|----------------------|------------------------------------|----------------------|------------------------|---|
| <b>National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis</b> | Active, not recruiting | MED                  | Rennes University Hospital         | RR                   | 266                    | <a href="https://ClinicalTrials.gov/show/NCT02937285">https://ClinicalTrials.gov/show/NCT02937285</a> |
| <b>Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis</b>  | Active, not recruiting | MED                  | Genzyme, a Sanofi Company   Sanofi | Relapsing, pediatric | 166                    | <a href="https://ClinicalTrials.gov/show/NCT02201108">https://ClinicalTrials.gov/show/NCT02201108</a> |
| <b>Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)</b>  | Active, not recruiting | MED                  | Novartis Pharma.   Novartis        | SP                   | 1652                   | <a href="https://ClinicalTrials.gov/show/NCT01665144">https://ClinicalTrials.gov/show/NCT01665144</a> |
| <b>A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2</b>   | Recruiting             | MED                  | Alkermes, Inc.                     | RR                   | 420                    | <a href="https://ClinicalTrials.gov/show/NCT03093324">https://ClinicalTrials.gov/show/NCT03093324</a> |

| Study title   | Recruitment status     | Type of Intervention | Sponsor/ Collaborators                      | Type of MS                     | Number of participants | Link for more information   |
|---|------------------------|----------------------|---|--------------------------------|------------------------|---|
| <b>Maximizing Outcome of Multiple Sclerosis Transplantation</b>   | Recruiting             | MED                  | Northwestern University                     | RR                             | 200                    | <a href="https://ClinicalTrials.gov/show/NCT03342638">https://ClinicalTrials.gov/show/NCT03342638</a> |
| <b>Rituximab Versus FUmurate in Newly Diagnosed Multiple Sclerosis.</b>   | Recruiting             | MED                  | Anders Svenningsson   Karolinska Institutet | RR                             | 200                    | <a href="https://ClinicalTrials.gov/show/NCT02746744">https://ClinicalTrials.gov/show/NCT02746744</a> |
| <b>ACTH for Fatigue in Multiple Sclerosis Patients</b>  | Active, not recruiting | MED                  | Providence Health & Services   Mallinckrodt | RR                             | 8                      | <a href="https://ClinicalTrials.gov/show/NCT02315872">https://ClinicalTrials.gov/show/NCT02315872</a> |
| <b>A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis</b>  | Recruiting             | MED                  | Hoffmann-La Roche                           | SP, PP                         | 600                    | <a href="https://ClinicalTrials.gov/show/NCT03523858">https://ClinicalTrials.gov/show/NCT03523858</a> |
| <b>Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis</b>  | Active, not recruiting | COMP/ALT             | MedDay Pharma. SA                           | All types, with optic neuritis | 105                    | <a href="https://ClinicalTrials.gov/show/NCT02220244">https://ClinicalTrials.gov/show/NCT02220244</a> |
| <b>A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)</b> | Recruiting             | MED                  | TG Therapeutics, Inc.                       | Relapsing                      | 440                    | <a href="https://ClinicalTrials.gov/show/NCT03277261">https://ClinicalTrials.gov/show/NCT03277261</a> |

| Study title  | Recruitment status     | Type of Intervention | Sponsor/ Collaborators | Type of MS | Number of participants | Link for more information   |
|--|------------------------|----------------------|------------------------|------------|------------------------|---|
| <b>A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)</b> | Recruiting             | MED                  | TG Therapeutics, Inc.  | Relapsing  | 440                    | <a href="https://ClinicalTrials.gov/show/NCT03277248">https://ClinicalTrials.gov/show/NCT03277248</a> |
| <b>Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)</b>  | Recruiting             | MED                  | Hoffmann-La Roche      | RR         | 600                    | <a href="https://ClinicalTrials.gov/show/NCT03085810">https://ClinicalTrials.gov/show/NCT03085810</a> |
| <b>BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)</b>  | Active, not recruiting | MED                  | Biogen                 | RR         | 1738                   | <a href="https://ClinicalTrials.gov/show/NCT00835770">https://ClinicalTrials.gov/show/NCT00835770</a> |

| Study title   | Recruitment status     | Type of Intervention | Sponsor/ Collaborators | Type of MS    | Number of participants | Link for more information   |
|---|------------------------|----------------------|------------------------|---------------|------------------------|---|
| <b>An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)</b>                                 | Active, not recruiting | MED                  | Biogen                 | RR            | 225                    | <a href="https://ClinicalTrials.gov/show/NCT01838668">https://ClinicalTrials.gov/show/NCT01838668</a> |
| <b>A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis</b>   | Active, not recruiting | MED                  | Hoffmann-La Roche      | Relapsing     | 835                    | <a href="https://ClinicalTrials.gov/show/NCT01412333">https://ClinicalTrials.gov/show/NCT01412333</a> |
| <b>Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019</b> | Active, not recruiting | MED                  | Biogen   AbbVie        | RR            | 1501                   | <a href="https://ClinicalTrials.gov/show/NCT01797965">https://ClinicalTrials.gov/show/NCT01797965</a> |
| <b>Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)</b>  | Active, not recruiting | MED                  | Biogen                 | RR, pediatric | 20                     | <a href="https://ClinicalTrials.gov/show/NCT02555215">https://ClinicalTrials.gov/show/NCT02555215</a> |



| Study title  | Recruitment status     | Type of Intervention | Sponsor/ Collaborators      | Type of MS | Number of participants | Link for more information   |
|--|------------------------|----------------------|-----------------------------|------------|------------------------|---|
| <b>A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis</b>  | Active, not recruiting | MED                  | Hoffmann-La Roche           | Relapsing  | 821                    | <a href="https://ClinicalTrials.gov/show/NCT01247324">https://ClinicalTrials.gov/show/NCT01247324</a> |
| <b>A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)</b> | Active, not recruiting | MED                  | Hoffmann-La Roche           | RR         | 681                    | <a href="https://ClinicalTrials.gov/show/NCT02861014">https://ClinicalTrials.gov/show/NCT02861014</a> |
| <b>Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis</b>   | Active, not recruiting | MED                  | Novartis Pharma.   Novartis | Relapsing  | 4125                   | <a href="https://ClinicalTrials.gov/show/NCT01201356">https://ClinicalTrials.gov/show/NCT01201356</a> |
| <b>A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis</b>   | Active, not recruiting | MED                  | Hoffmann-La Roche           | Relapsing  | 102                    | <a href="https://ClinicalTrials.gov/show/NCT02545868">https://ClinicalTrials.gov/show/NCT02545868</a> |

| <b>Study title</b>   | <b>Recruitment status</b> | <b>Type of Intervention</b> | <b>Sponsor/ Collaborators</b>  | <b>Type of MS</b>       | <b>Number of participants</b> | <b>Link for more information</b>  |
|--|---------------------------|-----------------------------|--|-------------------------|-------------------------------|---|
| <b>Vitamin D Supplementation in Multiple Sclerosis</b>   | Recruiting                | COMP/ALT                    | Johns Hopkins University, etc.   | RR                      | 172                           | <a href="https://ClinicalTrials.gov/show/NCT01490502">https://ClinicalTrials.gov/show/NCT01490502</a> |
| <b>A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)</b> | Recruiting                | MED                         | Genentech, Inc.  | RR                      | 611                           | <a href="https://ClinicalTrials.gov/show/NCT02637856">https://ClinicalTrials.gov/show/NCT02637856</a> |
| <b>Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis</b>   | Recruiting                | MED                         | Johns Hopkins University  Patient-Centered Outcomes Research Institute | All types, with fatigue | 136                           | <a href="https://ClinicalTrials.gov/show/NCT03185065">https://ClinicalTrials.gov/show/NCT03185065</a> |
| <b>Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)</b>   | Recruiting                | MED                         | Biogen   | RR                      | 142                           | <a href="https://ClinicalTrials.gov/show/NCT02283853">https://ClinicalTrials.gov/show/NCT02283853</a> |
| <b>Multiple Sclerosis-Simvastatin Trial 2</b>  | Not yet recruiting        | MED                         | University College, London, etc.                                       | SP                      | 1180                          | <a href="https://ClinicalTrials.gov/show/NCT03387670">https://ClinicalTrials.gov/show/NCT03387670</a> |

| <b>Study title</b>  | <b>Recruitment status</b> | <b>Type of Intervention</b> | <b>Sponsor/ Collaborators</b>           | <b>Type of MS</b>                  | <b>Number of participants</b> | <b>Link for more information</b>  |
|---|---------------------------|-----------------------------|---|------------------------------------|-------------------------------|---|
| <b>A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis</b>                 | Active, not recruiting    | MED                         | Hoffmann-La Roche                       | PP                                 | 732                           | <a href="https://ClinicalTrials.gov/show/NCT01194570">https://ClinicalTrials.gov/show/NCT01194570</a> |
| <b>A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment</b> | Not yet recruiting        | MED                         | Adamas Pharma., Inc.                    | All types, with walking impairment | 540                           | <a href="https://ClinicalTrials.gov/show/NCT03567057">https://ClinicalTrials.gov/show/NCT03567057</a> |
| <b>Effects of Acthar on Recovery From Cognitive Relapses in MS</b>  | Enrolling by invitation   | MED                         | State University of New York at Buffalo | RR, SP, with cognitive symptoms    | 60                            | <a href="https://ClinicalTrials.gov/show/NCT02290444">https://ClinicalTrials.gov/show/NCT02290444</a> |
| <b>Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment</b>             | Recruiting                | MED                         | Adamas Pharma., Inc.                    | All types, with walking impairment | 540                           | <a href="https://ClinicalTrials.gov/show/NCT03436199">https://ClinicalTrials.gov/show/NCT03436199</a> |
| <b>RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS</b>          | Recruiting                | MED                         | Haukeland University Hospital           | RR                                 | 100                           | <a href="https://ClinicalTrials.gov/show/NCT03477500">https://ClinicalTrials.gov/show/NCT03477500</a> |

| Study title  | Recruitment status     | Type of Intervention | Sponsor/ Collaborators                    | Type of MS    | Number of participants | Link for more information   |
|--|------------------------|----------------------|---|---------------|------------------------|---|
| <b>Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)</b> | Recruiting             | MED                  | Genentech, Inc.                           | Relapsing, PP | 104                    | <a href="https://ClinicalTrials.gov/show/NCT02688985">https://ClinicalTrials.gov/show/NCT02688985</a> |
| <b>A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT</b>  | Recruiting             | MED                  | Genzyme, a Sanofi Company   Sanofi        | RR            | 50                     | <a href="https://ClinicalTrials.gov/show/NCT03368664">https://ClinicalTrials.gov/show/NCT03368664</a> |
| <b>Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab</b>  | Active, not recruiting | MED                  | Biogen   AbbVie                           | RR            | 100                    | <a href="https://ClinicalTrials.gov/show/NCT02881567">https://ClinicalTrials.gov/show/NCT02881567</a> |
| <b>Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome</b>  | Recruiting             | COMP/ALT             | Centre Hospitalier Universitaire de N mes | CIS           | 316                    | <a href="https://ClinicalTrials.gov/show/NCT01817166">https://ClinicalTrials.gov/show/NCT01817166</a> |

| Study title   | Recruitment status | Type of Intervention | Sponsor/ Collaborators  | Type of MS                 | Number of participants | Link for more information   |
|---|--------------------|----------------------|---|----------------------------|------------------------|---|
| <b>A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS</b>          | Not yet recruiting | MED                  | Bosnalijek D.D MonitorC RO  | RR                         | 400                    | <a href="https://ClinicalTrials.gov/show/NCT03283397">https://ClinicalTrials.gov/show/NCT03283397</a> |
| <b>Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome</b> | Recruiting         | MED                  | Centre Hospitalier Universitaire de Nice  Genzyme, a Sanofi Company   | RIS                        | 200                    | <a href="https://ClinicalTrials.gov/show/NCT03122652">https://ClinicalTrials.gov/show/NCT03122652</a> |
| <b>Pilot Study of Transcranial Direct Current Stimulation (tDCS)</b>  | Recruiting         | REHAB                | New York University School of Medicine  Stony Brook University        | All types                  | 115                    | <a href="https://ClinicalTrials.gov/show/NCT02746705">https://ClinicalTrials.gov/show/NCT02746705</a> |
| <b>" Treating MS Patients With Lower Extremity Spasticity Using Dysport"</b>  | Recruiting         | MED                  | Neurology Center of New England P.C.  Ipsen                           | All types, with spasticity | 30                     | <a href="https://ClinicalTrials.gov/show/NCT03585569">https://ClinicalTrials.gov/show/NCT03585569</a> |
| <b>A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis</b>   | Not yet recruiting | MED                  | Immune Response BioPharma, Inc.  Oregon Health and Science University | SP                         | 200                    | <a href="https://ClinicalTrials.gov/show/NCT02057159">https://ClinicalTrials.gov/show/NCT02057159</a> |

| Study title   | Recruitment status     | Type of Intervention | Sponsor/ Collaborators                 | Type of MS                 | Number of participants | Link for more information   |
|---|------------------------|----------------------|--|----------------------------|------------------------|---|
| <b>A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS</b> | Recruiting             | MED                  | Osmotica Pharma. US LLC                | All types, with spasticity | 250                    | <a href="https://ClinicalTrials.gov/show/NCT03319732">https://ClinicalTrials.gov/show/NCT03319732</a> |
| <b>Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.</b>             | Active, not recruiting | MED                  | Novartis Pharma.   Novartis            | Relapsing                  | 956                    | <a href="https://ClinicalTrials.gov/show/NCT02792231">https://ClinicalTrials.gov/show/NCT02792231</a> |
| <b>A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS</b>        | Recruiting             | MED                  | Osmotica Pharma. US LLC                | All types, with spasticity | 510                    | <a href="https://ClinicalTrials.gov/show/NCT03290131">https://ClinicalTrials.gov/show/NCT03290131</a> |
| <b>Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Active Progressive Multiple Sclerosis Patients</b>   | Not yet recruiting     | MED                  | Isfahan University of Medical Sciences | SP, with relapses          | 60                     | <a href="https://ClinicalTrials.gov/show/NCT03315923">https://ClinicalTrials.gov/show/NCT03315923</a> |

| Study title  | Recruitment status     | Type of Intervention | Sponsor/ Collaborators                                     | Type of MS                | Number of participants | Link for more information   |
|--|------------------------|----------------------|--|---------------------------|------------------------|---|
| <b>Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Relmitting-relapsing Multiple Sclerosis</b>                   | Active, not recruiting | MED                  | Biocad   | RR                        | 399                    | <a href="https://ClinicalTrials.gov/show/NCT02744222">https://ClinicalTrials.gov/show/NCT02744222</a> |
| <b>Advanced MRI Measures of Repair in Alemtuzumab Treated Patients</b>   | Active, not recruiting | MED                  | University of British Columbia   Genzyme, a Sanofi Company | RR                        | 25                     | <a href="https://ClinicalTrials.gov/show/NCT01307332">https://ClinicalTrials.gov/show/NCT01307332</a> |
| <b>A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis</b> | Recruiting             | MED                  | AB Science   | PP, SP (without relapses) | 450                    | <a href="https://ClinicalTrials.gov/show/NCT01433497">https://ClinicalTrials.gov/show/NCT01433497</a> |
| <b>Adderall XR and Cognitive Impairment in MS</b>  | Recruiting             | MED                  | Sarah Morrow   London Health Sciences Centre               | All types                 | 180                    | <a href="https://ClinicalTrials.gov/show/NCT02676739">https://ClinicalTrials.gov/show/NCT02676739</a> |

| Study title  | Recruitment status     | Type of Intervention | Sponsor/ Collaborators   | Type of MS                     | Number of participants | Link for more information   |
|--|------------------------|----------------------|--|--------------------------------|------------------------|---|
| <b>Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2</b> | Recruiting             | MED                  | Ipsen  | All types, with spasticity     | 408                    | <a href="https://ClinicalTrials.gov/show/NCT02660359">https://ClinicalTrials.gov/show/NCT02660359</a> |
| <b>Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1</b> | Recruiting             | MED                  | Ipsen  | All types, with spasticity     | 408                    | <a href="https://ClinicalTrials.gov/show/NCT02660138">https://ClinicalTrials.gov/show/NCT02660138</a> |
| <b>Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial</b>   | Active, not recruiting | MED                  | University Eye Hospital, Freiburg  German Federal Ministry of Education and Research | All types, with optic neuritis | 100                    | <a href="https://ClinicalTrials.gov/show/NCT01962571">https://ClinicalTrials.gov/show/NCT01962571</a> |